

DAFTAR PUSTAKA

1. American Cancer Society. *Cancer Facts and Figures*. Atlanta. 2014; p4-5.
2. Zahari A. Deteksi dini, diagnosa dan penatalaksanaan kanker kolon dan rektum. (tesis). Padang: Fakultas Kedokteran Universitas Andalas; 2011.
3. Hamilton, S.R., Vogelstein, B., Kudo, S., Riboli, E., Nakamura, S., Hainaut, P. 2009 Tumours of the colon and rectum. In: Hamilton SR, Aaltonen A, editors. World Health Organization: classification of tumours, pathology and genetics of tumours of the digestive system. Third ed. Lyon: IARC Press. p. 104-19.
4. American Joint Committee on Cancer. *AJCC Cancer Staging Manual 6th ed.* New York, NY: Springer; 2002.
5. Notoatmodjo Soekidjo. *Metodologi Penelitian Kesehatan*. Rineka Cipta: Jakarta. 2012
6. Altomare, D.F., Di Lena, M. & Giuratrabocchetta, S., 2012. MicroRNA: Future perspectives in colorectal cancer. *Colorectal Disease*, 14(2), pp.133–134.
7. Aran, V. et al., 2016. SC. *Clinical Colorectal Cancer*.
8. Ferri, F., 2016. Colorectal cancer. In : Ferri's Clinical Advisor 2016
9. Brenner, H., Kloor, M. & Pox, C.P., 2014. Colorectal cancer. *The Lancet*, 383(9927), pp.1490–1502.
10. Bresalier, R.S., 2016. Early detection of and screening for colorectal neoplasia. *Gut and liver*, 3(2), pp.69–80.
11. Esquela-Kerscher, A. & Slack, F.J., 2006. Oncomirs - microRNAs with a role in cancer. *Nature reviews. Cancer*, 6(4), pp.259–69.
12. Fearon, E.R. & Vogelstein, B., 1990. A genetic model for colorectal tumorigenesis. *Cell*, 61(5), pp.759–767.
13. Ferlay, J. et al., 2012. Cancer incidence and mortality worldwide : sources , methods and major patterns in GLOBOCAN 2012.
14. Kemkes, 2014. Panduan Penatalaksanaan Kanker kolorektal.
15. Khosama, 2015. Faktor Risiko Kanker Kolorektal. , 42(11), pp.829–832.
16. Kim, J.W., Shin, M.K. & Kim, B.C., 2015. Clinicopathologic Impacts of Poorly Differentiated Cluster-Based Grading System in Colorectal Carcinoma. , pp.16–23.
17. Kresno, S.B., 2011. MicroRNA dan implikasinya pada kanker. *Indonesian Journal of Cancer*, 5(3), pp.119–27.

18. Labianca, R. et al., 2010. Primary colon cancer: ESMO clinical practice guidelines for diagnosis, adjuvant treatment and follow-up. *Annals of Oncology*, 21(SUPPL. 5), pp.70–77.
19. Liu, G.-H. et al., 2013. Serum miR-21 and miR-92a as biomarkers in the diagnosis and prognosis of colorectal cancer. *Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine*, 34(4), pp.2175–2181.
20. Thomas, J. et al., 2015. MicroRNAs: Clinical relevance in colorectal cancer. *International Journal of Molecular Sciences*, 16(12), pp.28063–28076.
21. Xu, P. et al., 2016. Colorectal cancer characterization and therapeutic target prediction based on microRNA expression profile. *Scientific reports*, 6(February), p.20616. Available at: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4745004&tool=pmcentrez&rendertype=abstract>.
22. Zhu, L. & Fang, J., 2016. The Structure and Clinical Roles of MicroRNA in Colorectal Cancer. *Gastroenterology Research and Practice*, 2016, pp.1–6. Available at: <https://www.hindawi.com/journals/grp/2016/1360348/>.
23. Abdullah M, Sudoyo AW, Utomo AR, Fauzi A, Rani AA. 2012. Molecular profile of colorectal cancer in Indonesia: is there another pathway? *Gastroenterology and Hepatology From Bed to Bench* 5(2): 71-78
24. Wang L, Qian L, Li X, Yan J. 2014. MicroRNA-195 inhibits colorectal cancer cell proliferation, colony-formation and invasion through targeting CARMA3. *Mol Med Rep* 10(1): 473-478
25. Kokki I, Papan A, Campbell H, Theodoratou E, 2013, Estimating the incidence of colorectal cancer in South East Asia. *Croat Med J*, 54: 532-540.
26. Kim JW, Shin MK, Kim BC, 2015, Clinicopathologic impacts of poorly differentiated cluster-based grading system in colorectal carcinoma. *J Korean Med Sci*, 30:16-23.
27. Buscaglia LEB, Li Y. 2011. Apoptosis and the Target Genes of MicroRNA-21. *Chin J Cancer* 30(6): 371-380
28. Weng W, Feng J, Qin H, Ma Y, and Goel A. 2015. An Update on MiRNAs as Biological and Clinical Determinants in Colorectal Cancer: a bench-to-bedside approach. *Future Oncology* 11(12): 1791–1808.
29. Ferlay, J, Soerjomataram I, Dikshit R. 2015. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer* 136: pp. E359E386
30. Burt R, and Neklason DW. 2005. Genetic testing for inherited colon cancer. *Gastroenterology* 128: 1696-1716

31. Herrinton LJ, Liu L, Levin TR, et al. 2012. Incidence and Mortality of Colorectal Adenocarcinoma in Persons with Inflammatory Bowel Disease from 1998 to 2010. *Gastroenterology* 143:382-389
32. Ahsan, H., Neugut, A.I., Garbowski, C.G. et al. Family history of colorectal adenomatous polyps and increased risk for colorectal cancer. *Ann Intern Med* 2008; 128: 900–5.
33. Fenoglio-Preiser C.M. 2009. editor. *Gastrointestinal pathology: an atlas and text*. Philadelphia: Lippincott Williams & Wilkins
34. Aalok Kumar HFK, Lim HJ, Renouf DJ, Woods R, Speers C, and Cheung Wy. 2012. Adjuvant chemotherapy (AC) use and outcomes in stage II colon cancer (CC) with and without poor prognostic features. *J Clin Oncol* 30
35. Andre T, Boni, Navarro M, et al. 2009 improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. *J Clin Oncol* 27: 3109-3116
36. Sargent DJ, Yothers G, et al. 2014. Prognostic impact of deficient mismatch repair (dMMR) in 7,803 stage II/III colon cancer (CC) patients (pts): a pooled individual pt data analysis of 17 adjuvant trials in the ACCENT database. *J Clin Oncol* 32: 5
37. Stiegelbauer V, Perakis S, Deutsch A, Ling H, Gerger A, Pichler M. 2014. MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer. *World J. Gastroenterol* 20, 11727–11735
38. Clark J, Grothey A Goldberg R. 2015. *Systemic Chemotherapy for Nonoperable Metastatic Colorectal Cancer: Treatment Recommendations*. UpToDate: Waltham, MA, USA, 2015
39. Schoenstadt A. Colon Cancer Prognosis serial online.2006 [cited 2017 May 2017]. <http://colon-cancer.emedtv.com/colon-cancer/colon-cancer-prognosis.html>
40. Xing J, Wan S, Zhou F, Qu F, Li B, Myers RE, Fu X, Palazzo JP, He X, Chen Z, Yang H. 2012. Genetic polymorphisms in pre-microRNA genes as prognostic markers of colorectal cancer. *Cancer Epidemiol. Biomark. Prev.* 21, 217–227.
41. Compton C. Tanabe K. 2015. *Pathology and Prognostic Determinants of CRC*. UpToDate: Waltham, MA, USA,
42. Bader A, Lammers P. The Therapeutic Potential of microRNAs. *Innov. Pharm. Technol.* Available online: <http://biology.westfield.ma.edu/biol104-501/sites/default/files/Therapeutic-Potential-microRNAs.pdf> (accessed on 15 July 2015).
43. Michael MZ, O'Connor SM, van Holst Pellekaan NG, Young GP, James RJ. 2003. Reduced accumulation of specific microRNAs in colorectal neoplasia. *Mol. Cancer Res* 1: 882–891.

44. Thomas J, Ohtsuka M, Pichler M, Ling H. 2015. MicroRNAs: Clinical Relevance in Colorectal Cancer. *International Journal of Molecular Science* 16: 28063-28076
45. Toiyama Y, Hur K, Tanaka K, Inoue Y, Kusunoki M, Boland CR, Goel A. 2014 Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer. *Ann. Surg* 259, 735–743.
46. Bartel DP. 2009. microRNA: target recognition and regulatory functions. *Cell* 136:215-233
47. Raisch J, Darfeuille-Michaud A, Nguyen HT. 2013. role of microRNAs in the immune system, inflammation and cancer. *World Journal Gastroenterology* 19:2985-2996
48. Wightman B, Ha I, Ruvkun G. 1993. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-14 mediated temporal pattern formation in *C. elegans*. *Cell* 75:855-862
49. Li QJ, Chau J, Ebert PJ, Sylvester G, Min H, Liu G, Braich R, Manoharan M, Soutschek J, Skare P, Klein LO, Davis MM, Chen CZ. 2007. miR-181a is an intrinsic modulator of T cell sensitivity and selection. *Cell* 129: 147-161
50. Yu H, Kortylewski M, Pardoll D. 2007. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. *Nat Rev Immunol* 7: 41-51
51. Wei J, Wang F, Kong LY, Xu S, Doucette T, Ferguson SD, Yang Y, McEnery K, Jethwa K, Gjyshi O, Qiao W, Levine NB, Lang FF, Rao G, Fuller GN, Calin GA, Heimerlberger AB. 2013. miR-124 inhibits STAT3 signaling to enhance T cell-mediated immune clearance of glioma. *Cancer Res* 73: 3913-3926
52. Van Cutsem E, Nordlinger B, Cervantes A. 2010. Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. *Annals of Oncology* 21 (Supl 5): v93-v97.
53. Xueqing Wang, Jiandong Wang, Henghui Ma, Jin Zhang, Xiaojun Zhou. 2012. Downregulation of miR-195 correlates with lymph node metastasis and poor prognosis in colorectal cancer. *Med Oncol* (2012) 29:919–927
54. Su BB, Shi H, Wan J. 2012. Role of serum carcinoembryonic antigen in the detection of colorectal cancer before and after surgical resection. *World J Gastroenterol*; 18(17): 2121-2126
55. Abdullah M, Sudoyo AW, Utomo AR, Fauzi A, Rani AA. 2012. Molecular profile of colorectal cancer in Indonesia: is there another pathway? *Gastroenterology and Hepatology From Bed to Bench* 5(2): 71-78
56. Gold P, Shuster J, Freedman SO. Carcinoembryonic antigen (CEA) in clinical medicine: historical perspectives, pitfalls and projections. *Cancer* 1978; 42: 1399-1405